Trilaciclib dihydrochloride - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for trilaciclib dihydrochloride and what is the scope of freedom to operate?
Trilaciclib dihydrochloride
is the generic ingredient in one branded drug marketed by G1 Therap and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Trilaciclib dihydrochloride has one hundred and ten patent family members in twenty-five countries.
One supplier is listed for this compound.
Summary for trilaciclib dihydrochloride
| International Patents: | 110 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 13 |
| DailyMed Link: | trilaciclib dihydrochloride at DailyMed |
Recent Clinical Trials for trilaciclib dihydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 4 |
| G1 Therapeutics, Inc. | Phase 4 |
US Patents and Regulatory Information for trilaciclib dihydrochloride
International Patents for trilaciclib dihydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2013543845 | See Plans and Pricing | |
| Denmark | 2968290 | See Plans and Pricing | |
| China | 103429243 | CDK inhibitors | See Plans and Pricing |
| China | 104045654 | CDK inhibitors | See Plans and Pricing |
| South Korea | 20190135556 | CDK 억제제 (CDK CDK INHIBITORS) | See Plans and Pricing |
| European Patent Office | 3653209 | PROTECTION TRANSITOIRE DE CELLULES NORMALES PENDANT LA CHIMIOTHÉRAPIE (TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
